These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32366671)

  • 21. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α.
    Qu Z; Wang S; Teng R; Yi X
    Mol Cell Biochem; 2014 Jan; 386(1-2):135-42. PubMed ID: 24114662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
    Marubayashi S; Koppikar P; Taldone T; Abdel-Wahab O; West N; Bhagwat N; Caldas-Lopes E; Ross KN; Gönen M; Gozman A; Ahn JH; Rodina A; Ouerfelli O; Yang G; Hedvat C; Bradner JE; Chiosis G; Levine RL
    J Clin Invest; 2010 Oct; 120(10):3578-93. PubMed ID: 20852385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
    Soudan H; Saeed H; Eldemellawy M; Shalaby M; Hassan M; Elkewedi M; El-Nikhely N
    Acta Biochim Pol; 2020 Dec; 67(4):561-570. PubMed ID: 33319549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of
    Sharma S; Kalidindi T; Joshi S; Digwal CS; Panchal P; Burnazi E; Lee SG; Pillarsetty N; Chiosis G
    STAR Protoc; 2022 Jun; 3(2):101318. PubMed ID: 35496791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).
    Liu M; Wang J; Wu X; Wang E; Baptista D; Scott B; Liu P
    J Pharm Biomed Anal; 2014 Feb; 89():34-41. PubMed ID: 24252723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
    Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
    Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.
    Krebs S; Veach DR; Carter LM; Grkovski M; Fornier M; Mauro MJ; Voss MH; Danila DC; Burnazi E; Null M; Staton K; Pressl C; Beattie BJ; Zanzonico P; Weber WA; Lyashchenko SK; Lewis JS; Larson SM; Dunphy MPS
    J Nucl Med; 2020 Nov; 61(11):1580-1587. PubMed ID: 32169913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.
    Trendowski M
    Pharmacol Res; 2015 Sep; 99():202-16. PubMed ID: 26117427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
    Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
    Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
    Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
    Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
    Pillarsetty N; Jhaveri K; Taldone T; Caldas-Lopes E; Punzalan B; Joshi S; Bolaender A; Uddin MM; Rodina A; Yan P; Ku A; Ku T; Shah SK; Lyashchenko S; Burnazi E; Wang T; Lecomte N; Janjigian Y; Younes A; Batlevi CW; Guzman ML; Roboz GJ; Koziorowski J; Zanzonico P; Alpaugh ML; Corben A; Modi S; Norton L; Larson SM; Lewis JS; Chiosis G; Gerecitano JF; Dunphy MPS
    Cancer Cell; 2019 Nov; 36(5):559-573.e7. PubMed ID: 31668946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
    Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
    Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-Man Evaluation of
    Laforest R; Dehdashti F; Liu Y; Frye J; Frye S; Luehmann H; Sultan D; Shan JS; Freimark BD; Siegel BA
    Mol Imaging; 2017; 16():1536012117733349. PubMed ID: 29037107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First clinical study of a pegylated diabody
    Scott AM; Akhurst T; Lee FT; Ciprotti M; Davis ID; Weickhardt AJ; Gan HK; Hicks RJ; Lee ST; Kocovski P; Guo N; Oh M; Mileshkin L; Williams S; Murphy D; Pathmaraj K; O'Keefe GJ; Gong SJ; Pedersen JS; Scott FE; Wheatcroft MP; Hudson PJ
    Theranostics; 2020; 10(25):11404-11415. PubMed ID: 33052222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
    Yuzefovych Y; Blasczyk R; Huyton T
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.